Day: June 29, 2022

Erdene Releases 2022 Shareholder Letter

Written by Customer Service on June 29, 2022. Posted in Public Companies.

HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) — Erdene Resource Development Corporation (TSX:ERD | MSE:ERDN) (“Erdene” or the “Company”) is pleased to provide its 2022 Letter to Shareholders authored by President and CEO, Peter Akerley. To read the letter please visit Letter to Shareholders. “Over the past year, we executed upon our mission of developing the Khundii Gold District for the benefit of all stakeholders,” said Peter Akerley, Erdene’s President and CEO. “As outlined in my letter to fellow shareholders, recent high-grade gold discoveries at Ulaan and Dark Horse position Erdene to achieve its two million ounce gold equivalent resource target later this year, with the potential to add significant resources beyond this target.” “We also made solid progress preparing our Bayan Khundii Gold Project for construction,...

SL Green Announces Closing of 450 Park Avenue Acquisition in Newly Formed Joint Venture

Written by Customer Service on June 29, 2022. Posted in Mergers And Acquisitions.

Mortgage Financing Provided by Wells Fargo NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it closed on the previously announced acquisition of 450 Park Avenue in a newly formed joint venture. The ownership group consists of institutional investors from South Korea and Israel. SL Green retained a 25.1 percent interest in the property and will oversee leasing and management of the property on behalf of the partnership. “The international demand to partner with us on the acquisition of 450 Park Avenue demonstrates that New York City continues to maintain its position as one of the most sought-after real estate markets and a safe haven for long-term capital deployment,” said Harrison Sitomer, Chief Investment Officer of SL Green. “The acquisition...

AVENIR LNG LIMITED REPORTS UNAUDITED FINANCIAL AND OPERATING RESULTS FOR THE QUARTER ENDED MARCH 31, 2022

Written by Customer Service on June 29, 2022. Posted in Earnings Releases And Operating Results.

June 29, 2022 – Avenir LNG Limited and its subsidiaries (NOTC: AVENIR) (“Avenir” or the “Company or Group”), supplies small-scale LNG to off-grid industry, power generation and transport fuel sectors as well as providing infrastructure to support the development of LNG as a marine fuel, today announced its unaudited financial and operating results for the first quarter ended March 31, 2022. Peter Mackey, Chief Executive Officer of Avenir commented: “Avenir is pleased to report operating revenues of $6.7 million and EBITDA of $0.8 million, for Q1 2022. We have begun 2022 in line with our operation plan for the full year and expect to see upside to our plan if we can capitalize on certain opportunities that have been created by volatility in the global gas and LNG markets. Security of supply has become a key priority for customers, especially...

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Written by Customer Service on June 29, 2022. Posted in Public Companies.

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endpoint Evaluating cycles 1-6, the imbalance increases further (79% of cycles on ALRN-6924 versus 57% on placebo)Interim finding on the trial’s composite primary endpoint, which was the proportion of treatment cycles free of Grade ≥3 neutropenia, anemia, thrombocytopenia, blood transfusions, use of growth factors, dose reductions/delays in the first 4 cycles, demonstrated 56% of cycles on ALRN-6924 versus 50% of cycles on placebo 25 of the total 83 cycles completed across both treatment arms showed Grade ≥3 hematologic toxicities (30%); only 3 patients...

Synlogic Announces Appointment of General Counsel and Corporate Secretary

Written by Customer Service on June 29, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Brendan St. Amant as General Counsel and Corporate Secretary effective July 1, 2022. “Since joining Synlogic last year, Brendan has been invaluable in his guidance and sound counsel on many complex legal and business issues,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “In his new role, Brendan will continue to provide strong leadership as the company continues its progress towards many important clinical and regulatory milestones.” Brendan joined Synlogic in 2021 as Vice President, Head of Legal. Prior to joining Synlogic,...

XPO Logistics Expands Use of Sustainable Biofuel at the Tour de France as Official Transport Partner for the 42nd Year

Written by Customer Service on June 29, 2022. Posted in Public Companies.

XPO’s HVO-powered trucks will emit up to 85% less CO2 than diesel GREENWICH, Conn., June 29, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, will take to the road in July for the 42nd year as the official transport partner of the Tour de France. When the winner of the legendary cycling competition is declared at the Champs-Élysées in Paris, an XPO team of 58 drivers will have transported more than 570 tons of goods over 3,328 kilometers in 42 trucks — and 18 of those trucks will be fueled by biodegradable hydrotreated vegetable oil (HVO). XPO first piloted biofuel at the 2021 Tour de France with a truck running on B100 fuel made from rapeseed oil. This year, the company expects its alternative-fuel fleet to use 49,000 liters of HVO and reduce CO2 emissions by up to...

Surface Oncology Appoints Carsten Brunn to Board of Directors

Written by Customer Service on June 29, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company’s board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. “I am thrilled to welcome Carsten to the Surface Oncology board,” said Rob Ross, M.D., chief executive officer at Surface. “Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we advance our mission of bringing important new IO therapies to patients in need.” Dr. Brunn is president and chief executive officer at Selecta Biosciences...

Tilray Medical Expands Portfolio of Medical Cannabis Products in the UK

Written by Customer Service on June 29, 2022. Posted in Public Companies.

LEAMINGTON, Ontario, June 29, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom. Tilray Medical now offers the broadest portfolio of cannabis flower in the UK market today, including a differentiated range of high THC products, cultivated at its EU-GMP-certified facility in Portugal. Denise Faltischek, Tilray’s Chief Strategy Officer, and Head of International Business, said, “The demand for medical cannabis in the UK is growing rapidly. We are incredibly proud to provide patients...

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Written by Customer Service on June 29, 2022. Posted in Public Companies.

Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached Global, randomized Phase 2 study of botensilimab/balstilimab in MSS CRC to begin this year Agenus to host webcast today at 10:00 AM EDTLEXINGTON, Mass., June 29, 2022 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced expanded data from the Phase 1b study of botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (anti-PD-1) in patients with microsatellite stable colorectal cancer (MSS CRC). The data demonstrate that the combination...

ChampionX Announces Second Quarter 2022 Earnings Release and Conference Call Schedule

Written by Customer Service on June 29, 2022. Posted in Public Companies.

THE WOODLANDS, Texas, June 29, 2022 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today that it will release its second quarter 2022 operating results on Tuesday, July 26, 2022, after the market closes. The Company has scheduled a conference call for Wednesday, July 27, 2022, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to discuss the results. The call will be available by live webcast on ChampionX’s website at https://investors.championx.com or by dialing in as follows:United States: 1-866-374-5140International: 1-404-400-0571Reference: ChampionX conference call number 11738857Please register for the webcast or dial into the call approximately 15 minutes prior to the scheduled start time. A replay of the conference call will be available for approximately 30...

Day: June 29, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice